Parties Vie For Place At EMA’s First Ever Public Hearing On Medicines Safety
Executive Summary
The first ever public hearing on the safety of marketed medicines being organized by the European Medicines Agency has drawn a “very positive” response from the members of the public who have applied to attend the event on Sept. 26. The agency is now shortlisting an appropriate mix of speakers and observers.
You may also be interested in...
UK Bans Valproate Use Without Pregnancy Prevention Program; First In EU To Do So?
Following the endorsement of EU-wide restrictions on the safe use of anti-epilepsy drug valproate, the UK appears to be the first member state to put in place a pregnancy prevention program to reduce the number of pregnancies exposed to valproate medicines to an absolute minimum and make sure all women and girls of childbearing potential are aware of the risks.
EMA Poses Three Questions For the Public Ahead Of Valproate Hearing
The European Medicines Agency will be choosing speakers for its public hearing on valproate in September based on how they propose to address three questions. Pharmaceutical companies can apply too.
Valproate In The Spotlight As EMA Releases Date For First Ever Public Hearing
The European Medicines Agency has released the date for its public hearing on valproate in which EU citizens will for the first time be given a voice in evaluating the safety of medicines on the market.